-
公开(公告)号：US20180193470A1
公开(公告)日：2018-07-12
申请号：US15852854
申请日：2017-12-22
申请人： Arvinas, Inc. , Yale University
发明人： Andrew P. Crew , Kurt Zimmermann , Jing Wang , Michael Berlin , Hanqing Dong , Alexey Ishchenko , Yimin Qian , Craig M. Crews , Saul Jaime-Figueroa , George Burslem
IPC分类号： A61K47/54 , A61K47/55 , A61K31/519 , A61K31/427 , A61K31/454 , A61K31/517 , A61K31/506 , A61K31/496 , A61K31/551 , A61K45/06 , A61K38/07 , A61K31/52 , A61K31/55
摘要： The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
2.发明申请公开(公告)号：US20160272639A1
公开(公告)日：2016-09-22
申请号：US15074820
申请日：2016-03-18
申请人： Arvinas, Inc. , Yale University
发明人： Andrew P. Crew , Craig M. Crews , Xin Chen , Hanqing Dong , Caterina Ferraro , Yimin Qian , Kam Siu , Jing Wang , Meizhong Jin , Michael Berlin , Kurt Zimmermann , Lawrence Snyder
IPC分类号： C07D471/04 , A61K31/427 , A61K45/06 , C07D417/12 , C07D403/06 , A61K31/4035 , C07D403/14 , A61K31/4155 , C07D401/14 , A61K31/454 , A61K31/4439 , A61K31/5377 , A61K31/437 , C07D413/14 , A61K31/4245 , C07D405/14 , A61K31/422 , A61K31/501 , A61K31/497 , A61K31/53 , C07D417/14
摘要： The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
摘要翻译： 本发明涉及双官能化合物，其可用作靶向泛素化的调节剂，特别是根据本发明的双官能化合物降解和/或以其它方式抑制的多种多肽和其它蛋白质的抑制剂。 特别地，本发明涉及化合物，其一端含有与泛素连接酶结合的VHL配体，另一端含有结合靶蛋白的部分，使得靶蛋白置于接近泛素连接酶 以实现该蛋白质的降解（和抑制）。 与靶向多肽的降解/抑制一致，本发明表现出与根据本发明的化合物相关的广泛的药理学活性。
-
公开(公告)号：US10730870B2
公开(公告)日：2020-08-04
申请号：US15074820
申请日：2016-03-18
申请人： Arvinas, Inc. , Yale University
发明人： Andrew P. Crew , Craig M. Crews , Xin Chen , Hanqing Dong , Caterina Ferraro , Yimin Qian , Kam Siu , Jing Wang , Meizhong Jin , Michael Berlin , Kurt Zimmermann , Lawrence Snyder
IPC分类号： C07D521/00 , C07D471/04 , C07D417/14 , A61K45/06 , C07D417/12 , C07D403/06 , C07D403/14 , C07D401/14 , C07D413/14 , C07D405/14 , C07D495/04
摘要： The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
-
公开(公告)号：US20180228907A1
公开(公告)日：2018-08-16
申请号：US15953108
申请日：2018-04-13
申请人： Arvinas, Inc.
发明人： Andrew P. Crew , Craig M. Crews , Hanqing Dong , Keith R. Hornberger , Jing Wang , Yimin Qian , Kurt Zimmermann , Michael Berlin , Lawrence B. Snyder
IPC分类号： A61K47/55 , C07D401/04 , C07D401/14 , C07D471/04 , A61K31/437 , A61K31/496 , A61K31/551 , A61K45/06 , A61K31/501 , A61K31/506 , A61K31/497
CPC分类号： A61K47/55 , A61K31/437 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/551 , A61K45/06 , A61K47/545 , A61P35/00 , C07D401/04 , C07D401/14 , C07D471/04
摘要： The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
-
公开(公告)号：US20180215731A1
公开(公告)日：2018-08-02
申请号：US15885671
申请日：2018-01-31
申请人： Arvinas, Inc.
发明人： Andrew P. Crew , Michael Berlin , Hanqing Dong , Keith R. Homberger , Yimin Qian , Lawrence B. Snyder , Jing Wang , Kurt Zimmermann
IPC分类号： C07D401/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D495/14 , C07D498/04 , A61P35/02
CPC分类号： C07D401/14 , A61P35/02 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D495/14 , C07D498/04
摘要： The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
-
公开(公告)号：US20180099940A1
公开(公告)日：2018-04-12
申请号：US15730728
申请日：2017-10-11
申请人： Arvinas, Inc.
发明人： Andrew P. Crew , Keith R. Hornberger , Lawrence B. Snyder , Kurt Zimmermann , Jing Wang , Michael Berlin , Craig M. Crews , Hanqing Dong
IPC分类号： C07D233/42 , C07D209/48 , C07D211/76 , C07D241/04 , C07D231/12 , C07D213/72 , C07D205/04 , C07D237/08 , C07D239/24 , C07D221/20 , A61K31/277 , A61K47/10 , A61K31/02 , A61K31/497 , A61K31/166
摘要： The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.
-
公开(公告)号：US20180346461A1
公开(公告)日：2018-12-06
申请号：US16048191
申请日：2018-07-27
申请人： Arvinas, Inc.
发明人： Andrew P. Crew , Hanqing Dong , Jing Wang , Xin Chen , Yimin Qian , Kurt Zimmermann , Craig M. Crews , Michael Berlin , Lawrence Snyder
IPC分类号： C07D417/14 , A61P25/28 , A61P35/00 , C07K5/078 , C07D413/14 , C07D417/12 , C07D471/10 , C07D491/107 , C07D401/04 , C07D233/86 , C07D413/12 , A61K45/06
CPC分类号： C07D417/14 , A61K45/06 , A61P25/28 , A61P35/00 , C07D233/86 , C07D401/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/10 , C07D491/107 , C07K5/06165
摘要： The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
-
8.发明申请公开(公告)号：US20190151295A1
公开(公告)日：2019-05-23
申请号：US16194094
申请日：2018-11-16
申请人： Arvinas, Inc.
IPC分类号： A61K31/437 , A61K31/422 , A61K31/427 , A61P35/00 , A61K31/551 , A61K38/53 , A61K38/20 , A61P37/06 , A61P21/04 , A61K47/64
摘要： The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号：US10994015B2
公开(公告)日：2021-05-04
申请号：US15852854
申请日：2017-12-22
发明人： Andrew P. Crew , Kurt Zimmermann , Jing Wang , Craig M. Crews , Saul Jaime-Figueroa , George Burslem
IPC分类号： C07D471/04 , A61P35/00 , A61K31/506 , A61K47/54 , A61K47/55 , A61K31/519 , A61K31/427 , A61K31/454 , A61K31/517 , A61K31/55 , A61K31/496 , A61K31/551 , A61K45/06 , A61K38/07 , A61K31/52
摘要： The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
10.发明授权公开(公告)号：US11986531B2
公开(公告)日：2024-05-21
申请号：US17387621
申请日：2021-07-28
发明人： Andrew P. Crew , Keith R. Hornberger , Jing Wang , Saul Jaime-Figueroa , Hanqing Dong , Kurt Zimmermann , Craig M. Crews
IPC分类号： C07D401/14 , A61K31/437 , A61K47/55 , A61P35/00 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
CPC分类号： A61K47/55 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
摘要： The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.044 秒)
